Choose Your Country or Region

Ipilimumab (anti-CTLA-4)

Synonyms: MDX-010, BMS-734016

Catalog No.A2001 Purity: 99.83%

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Ipilimumab (anti-CTLA-4) Chemical Structure

Click to purchase the isotype control of Ipilimumab (anti-CTLA-4)

Selleck's Ipilimumab (anti-CTLA-4) has been cited by 14 publications

Purity & Quality Control

Batch: Purity: 99.83% Protein concentration: 5mg/ml Endotoxin Level: ≤1 EU/mg

99.83

Choose Selective Immunology & Inflammation related Inhibitors

Biological Activity

Description

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Features

Human IgG1

Targets

CTLA-4 ^[1]
(Cell-free assay)

In Vitro
In vitro	Pembrolizumab plus ipilimumab and nivolumab plus ipilimumab with chemotherapy have been approved by FDA for the first-line treatment of NSCLC patients.^[1]
Cell Research:	For the intracellular cytokine analysis of TILs, cells from dissociated tumors in the density range of 1×10⁵ to 1×10⁶ cells were cultured in a 96-well U-bottom plate containing 10 µg/mL of pembrolizumab, 10 µg/mL of ipilimumab, soluble 50 ng/mL of anti-CD3, and 50 ng/mL of anti-CD28 for 24 h at 37°C, followed by the addition of brefeldin A and monensin. To measure interferon (IFN)-γ and tumor necrosis factor (TNF) secretion levels by CD8⁺ TILs according to PD-1 expression on anti-CD3 and anti-CD28 stimulation, the pre-incubation step without brefeldin A and monensin for 24 h was omitted. After 12 h, the cells were harvested and stained. Intracellular cytokines were stained after surface staining, fixation, and permeabilization with Foxp3 fixation/permeabilization solution.

In Vitro

In vitro

Pembrolizumab plus ipilimumab and nivolumab plus ipilimumab with chemotherapy have been approved by FDA for the first-line treatment of NSCLC patients.^[1]

Cell Research:

For the intracellular cytokine analysis of TILs, cells from dissociated tumors in the density range of 1×10⁵ to 1×10⁶ cells were cultured in a 96-well U-bottom plate containing 10 µg/mL of pembrolizumab, 10 µg/mL of ipilimumab, soluble 50 ng/mL of anti-CD3, and 50 ng/mL of anti-CD28 for 24 h at 37°C, followed by the addition of brefeldin A and monensin. To measure interferon (IFN)-γ and tumor necrosis factor (TNF) secretion levels by CD8⁺ TILs according to PD-1 expression on anti-CD3 and anti-CD28 stimulation, the pre-incubation step without brefeldin A and monensin for 24 h was omitted. After 12 h, the cells were harvested and stained. Intracellular cytokines were stained after surface staining, fixation, and permeabilization with Foxp3 fixation/permeabilization solution.

In Vivo
In vivo	⁶⁴Cu-labeled ipilimumab may be used to noninvasively monitor CTLA-4-expressing tissues in vivo.^[2]
Animal Research	AnimalModels:Female athymic nude mice of human lung adenocarcinoma xenograft model Formulation:buffer-exchanged to PBS, and conjugated with DOTA for radiolabeling with ⁶⁴Cu (t1/2 = 12.7 h) Dosages:~1 mg/mL Administration:i.v.^[2]

In Vivo

In vivo

⁶⁴Cu-labeled ipilimumab may be used to noninvasively monitor CTLA-4-expressing tissues in vivo.^[2]

Animal Research

AnimalModels:Female athymic nude mice of human lung adenocarcinoma xenograft model
Formulation:buffer-exchanged to PBS, and conjugated with DOTA for radiolabeling with ⁶⁴Cu (t1/2 = 12.7 h)
Dosages:~1 mg/mL
Administration:i.v.^[2]

References
[1] Kim CG, et al. J Immunother Cancer. 2021 Dec;9(12):e002780. [2] Ehlerding EB, et al. Mol Pharm. 2017 May 1;14(5):1782-1789.

References

Product Details

CAS No.	477202-00-9
Isotype	Human IgG1
Source	CHO cells
Formulation	PBS buffer, pH 7.2
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.